Table 1.
Patients Characteristics According to FGFR1 Amplification Status and Immunohistochemistry.
| Characteristics | FGFR1 FISH |
p Value | FGFR1 Protein
Expression |
p Value | ||
|---|---|---|---|---|---|---|
| Amplified (%) | Nonamplified (%) | High (%) | Low (%) | |||
| Number of patients | 14 (15.7%) | 75 (84.3%) | 35 (39.3%) | 53 (59.6%) | ||
| Age, years | ||||||
| Median (range) | 52.8 (±12.02) | 55.6 (±10.01) | 0.489a | 52.3 (±9.82) | 57.0 (±10.41) | 0.227a |
| Sex | ||||||
| Male | 13 (16.0%) | 68 (84.0%) | 0.793 | 32 (40.0%) | 48 (60.0%) | 0.890 |
| Female | 1 (12.5%) | 7 (87.5%) | 3 (37.5%) | 5 (62.5%) | ||
| Size (cm) | ||||||
| ≤4 | 13 (16.7%) | 65 (83%) | 0.518b | 34 (44.2%) | 43 (55.8%) | 0.044b |
| >4 | 1 (9.1%) | 10 (90.9%) | 1 (9.1%) | 10 (90.9%) | ||
| Differentiation | ||||||
| WD | 3 (18.8%) | 13 (81.3%) | 0.353 | 7 (43.8%) | 9 (56.3%) | 0.695 |
| MD | 8 (12.7%) | 55 (87.3%) | 23 (37.1%) | 39 (629%) | ||
| PD | 3 (30.0%) | 7 (70.0%) | 5 (50.0%) | 5 (50.0%) | ||
| Keratinization | ||||||
| Keratinizing | 4 (12.9%) | 27 (87.1%) | 0.763 | 16 (53.3%) | 14 (46.7%) | 0.071 |
| Non-keratinizing | 10 (17.2%) | 48 (82.8%) | 19 (32.8%) | 39 (60.2%) | ||
| LN metastasis | ||||||
| Present | 12 (15.2%) | 67 (84.7%) | 0.654b | 32 (41.0%) | 46 (59.0%) | 0.734b |
| Absent | 2 (20.0%) | 8 (80.0%) | 3 (30.0%) | 7 (70.0%) | ||
| pT stage | ||||||
| T1 | 4 (11.4%) | 31 (88.6%) | 0.609 | 19 (54.3%) | 16 (45.7%) | 0.080 |
| T2 | 8 (21.6%) | 29 (78.4%) | 13 (36.2%) | 23 (63.9%) | ||
| T3 | 1 (9.1%) | 10 (90.9%) | 2 (18.2%) | 9 (81.8%) | ||
| T4 | 1 (9.1%) | 5 (83.3%) | 1 (16.7%) | 5 (83.3%) | ||
| pN stage | ||||||
| N0 | 2 (20.0%) | 8 (80.0%) | 0.790 | 3 (30.0%) | 7 (70.0%) | 0.279 |
| N1 | 2 (12.5%) | 14 (87.5%) | 10 (62.5%) | 6 (37.5%) | ||
| N2a | 1 (11.1%) | 8 (88.9%) | 4 (44.4%) | 5 (55.6%) | ||
| N2b | 9 (19.6%) | 37 (80.4%) | 15 (33.3%) | 30 (66.7%) | ||
| N2c | 0 (0.0%) | 6 (100.0%) | 3 (50.0%) | 3 (50.0%) | ||
| N3 | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 2 (100.0%) | ||
| pTNM stage | ||||||
| I | 1 (20.0%) | 4 (80.0%) | 0.795 | 3 (60.0%) | 2 (40.0%) | 0.092 |
| II | 0 (0.0%) | 4 (100.0%) | 0 (0.0%) | 4 (100.0%) | ||
| III | 3 (20.0%) | 12 (80.0%) | 9 (60.0%) | 6 (40.0%) | ||
| IV | 10 (15.4%) | 55 (84.6%) | 23 (35.9%) | 41 (64.1%) | ||
| Smoking history | ||||||
| Never smoker | 5 (17.9%) | 23 (82.1%) | 0.155 | 12 (42.9%) | 16 (57.1%) | 0.920 |
| Former smoker | 3 (37.5%) | 5 (62.5%) | 3 (37.5%) | 5 (62.5%) | ||
| Current smoker | 6 (11.3%) | 47 (88.7%) | 20 (38.5%) | 32 (61.5%) | ||
| Alcohol history | ||||||
| Never/social | 6 (11.3%) | 47 (88.7%) | 0.297 | 21 (39.6%) | 32 (60.4%) | 0.985 |
| Yes | 8 (22.2%) | 28 (77.8%) | 14 (40.0%) | 21 (60.0%) | ||
| HPV ISH | ||||||
| Positive | 10 (16.9%) | 49 (83.1%) | 0.765b | 24 (41.4%) | 34 (58.6%) | 0.819b |
| Negative | 4 (13.3%) | 26 (86.7%) | 11 (36.7%) | 19 (63.3%) | ||
| p16 IHC | ||||||
| Positive | 9 (12.2%) | 65 (87.8%) | 0.055b | 31 (42.5%) | 42 (57.5%) | 0.386b |
| Negative | 5 (33.3%) | 10 (66.7%) | 4 (26.7%) | 11 (73.3%) | ||
| FGFR1 IHC | ||||||
| Positive | 6 (17.4%) | 29 (82.6%) | 0.797 | |||
| Negative | 8 (15.1%) | 45 (84.9%) | ||||
Abbreviations: FGFR1, fibroblast growth factor receptor 1; FISH, fluorescence in situ hybridization; HPV, human papillomavirus; ISH, in situ hybridization; IHC, immunohistochemistry; WD, well differentiated; MD, moderatedly differentiated; PD, poorly differentiated; LN, lymph node.
a
t-test.
b
Fisher’s exact test.